Ken Griffin Arvinas, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$23.66 - $32.73 $85,176 - $117,827	-3,600 Reduced 11.88%	26,700 $657,000
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $132,084 - $218,160	-5,400 Reduced 15.13%	30,300 $806,000
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $261,936 - $376,632	7,200 Added 25.26%	35,700 $1.47 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $329,208 - $982,056	23,200 Added 437.74%	28,500 $1.17 Million
Q3 2023 Nov 14, 2023	SELL	$19.64 - $28.21 $365,304 - $524,706	-18,600 Reduced 77.82%	5,300 $104,000
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $176,013 - $254,583	8,100 Added 51.27%	23,900 $593,000
Q1 2023 May 15, 2023	SELL	$26.15 - $37.26 $73,220 - $104,328	-2,800 Reduced 15.05%	15,800 $431,000
Q4 2022 Feb 14, 2023	SELL	$32.47 - $57.24 $928,642 - $1.64 Million	-28,600 Reduced 60.59%	18,600 $636,000
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $347,521 - $481,317	8,300 Added 21.34%	47,200 $2.1 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.